Overview

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Status:
Active, not recruiting

Trial end date:
2022-03-09

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety, tolerability, antiretroviral activity, and pharmacokinetics of 3 doses of islatravir (MK-8591) in combination with doravirine (DOR) and lamivudine (3TC) administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.

Phase:

Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Islatravir
Lamivudine
Tenofovir